Screener
Neurocrine Biosciences NBIX Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Net income | $197.9 | $7.9 |
| Foreign currency translation adjustments, net of tax | — | 1.5 |
| Unrealized (loss) gain on available-for-sale debt securities, net of tax | (12.7) | 1.7 |
| Comprehensive income | $185.2 | $11.1 |
| Earnings per share: | ||
| Basic | $1.97 | $0.08 |
| Diluted | $1.91 | $0.08 |
| Weighted-average shares outstanding: |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's comprehensive income (loss), net of tax, attributable to parent?
- Neurocrine Biosciences (NBIX) reported comprehensive income (loss), net of tax, attributable to parent of $185.2M in Q1 2026.
- How has Neurocrine Biosciences's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Neurocrine Biosciences's comprehensive income (loss), net of tax, attributable to parent increased by 1568.5% year-over-year, from $11.1M to $185.2M.
- What is the long-term trend for Neurocrine Biosciences's comprehensive income (loss), net of tax, attributable to parent?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's comprehensive income (loss), net of tax, attributable to parent has grown at a 48.5% compound annual growth rate (CAGR), from $148.3M to $485.9M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items like unrealized gains or losses on securities. It provides a holistic view of the company's financial performance by including items that bypass the traditional income statement. Investors use this to evaluate the broader financial health and total value creation of the enterprise.
Ask your AI about Neurocrine Biosciences's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude